文献速递帕金森病与运动障碍

伴动眼失用型共济失调1型的临床、生物标志物与分子特征及基因型-表型相关性

Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1.
PubMed 文献 · JAMA Neurol · 2018-01-01

该回顾性分析纳入单中心遗传实验室2002年至2014年连续诊断的80例伴动眼失用型共济失调1型(AOA1)患者,描述其临床、生物标志物及分子特征。结果发现α-甲胎蛋白(AFP)在41%患者中升高,低白蛋白血症见于63%,p.Trp279*突变最常见(66%),动眼失用与更严重表型及截短突变相关。

要点

  • AFP轻度升高见于41%的AOA1患者,可能成为新的生物标志物。
  • 动眼失用并非AOA1必备表现,出现时与更严重疾病相关。
  • p.Trp279*是白人人群中最常见的APTX突变。

核心结论

  • AFP水平在相当一部分AOA1患者中轻度升高,可能构成新的生物标志物。
  • 动眼失用可能是AOA1的可选表现,并与更严重的疾病相关。
  • p.Trp279*突变是白人人群中最常见的APTX突变。
  • APTX错义突变可能与更温和的表型相关。

研究设计与样本

  • 回顾性分析纳入2002年1月1日至2014年12月31日单中心遗传实验室连续诊断的AOA1患者80例(46例男性[58%],34例女性[42%];平均[SD]起病年龄7.7[7.4]岁),来自51个家系,包括57例新诊断患者(含8个新突变)和23例既往报道患者。

主要发现

  • 33例患者(41%)发现AFP水平升高,50例(63%)存在低白蛋白血症。
  • AOA1患者AFP中位水平为6.0 ng/mL(范围1.1-17.0 ng/mL),高于无共济失调患者的3.4 ng/mL(范围0.8-17.2 ng/mL;P < .01)。
  • 白蛋白水平降低(ρ = -0.532)和AFP水平升高(ρ = 0.637)与疾病持续时间相关。
  • p.Trp279*突变在53例AOA1患者(66%)中发现,具有广泛的白人种族起源。
  • 动眼失用于49例(61%)患者中发现,多神经病于74例(93%),小脑萎缩于78例(98%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ataxia with oculomotor apraxia type 1 (AOA1) is an autosomal recessive cerebellar ataxia due to mutations in the aprataxin gene (APTX) that is characterized by early-onset cerebellar ataxia, oculomotor apraxia, axonal motor neuropathy, and eventual decrease of albumin serum levels. OBJECTIVES: To improve the clinical, biomarker, and molecular delineation of AOA1 and provide genotype-phenotype correlations. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis included the clinical, biological (especially regarding biomarkers of the disease), electrophysiologic, imaging, and molecular data of all patients consecutively diagnosed with AOA1 in a single genetics laboratory from January 1, 2002, through December 31, 2014. Data were analyzed from January 1, 2015, through January 31, 2016. MAIN OUTCOMES AND MEASURES: The clinical, biological, and molecular spectrum of AOA1 and genotype-phenotype correlations. RESULTS: The diagnosis of AOA1 was confirmed in 80 patients (46 men [58%] and 34 women [42%]; mean [SD] age at onset, 7.7 [7.4] years) from 51 families, including 57 new (with 8 new mutations) and 23 previously described patients. Elevated levels of α-fetoprotein (AFP) were found in 33 patients (41%); hypoalbuminemia, in 50 (63%). Median AFP level was higher in patients with AOA1 (6.0 ng/mL; range, 1.1-17.0 ng/mL) than in patients without ataxia (3.4 ng/mL; range, 0.8-17.2 ng/mL; P < .01). Decreased albumin levels (ρ = -0.532) and elevated AFP levels (ρ = 0.637) were correlated with disease duration. The p.Trp279* mutation, initially reported as restricted to the Portuguese founder haplotype, was discovered in 53 patients with AOA1 (66%) with broad white racial origins. Oculomotor apraxia was found in 49 patients (61%); polyneuropathy, in 74 (93%); and cerebellar atrophy, in 78 (98%). Oculomotor apraxia correlated with the severity of ataxia and mutation type, being more frequent with deletion or truncating mutations (83%) than with presence of at least 1 missense variant (17%; P < .01). Mean (SD) age at onset was higher for patients with at least 1 missense mutation (17.7 [11.4] vs 5.2 [2.6] years; P < .001). CONCLUSIONS AND RELEVANCE: The AFP level, slightly elevated in a substantial fraction of patients, may constitute a new biomarker for AOA1. Oculomotor apraxia may be an optional finding in AOA1 and correlates with more severe disease. The p.Trp279* mutation is the most frequent APTX mutation in the white population. APTX missense mutations may be associated with a milder phenotype.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Renaud M, Moreira MC, Ben Monga B, et al. Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1. JAMA Neurol. 2018. PMID: 29356829. doi:10.1001/jamaneurol.2017.4373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。